Advanced search
1 file | 331.35 KB

Targeted therapy for metastatic renal cell cancer

CAROLINE VERBAEYS (UGent), Piet Hoebeke (UGent), Simon Van Belle (UGent) and Sylvie Rottey (UGent)
(2010) ACTA CLINICA BELGICA. 65(2). p.115-121
Author
Organization
Abstract
Renal cell cancer is a common urological malignancy for which the incidence has doubled over the last three decades. Thirty percent of patients have metastatic disease at the moment of diagnosis. Thirty percent of the remaining surgically treated patients will develop metastases. Before the introduction of targeted therapies the only therapeutic option for these patients was immunotherapy with bad tolerability and poor results. This review discusses these new 'targeted therapies'.
Keywords
IMMUNOTHERAPY, SUNITINIB, TEMSIROLIMUS, SORAFENIB, CARCINOMA, DOUBLE-BLIND, INTERFERON-ALPHA, PHASE-III TRIAL, targeted therapy, renal cell cancer, metastasis

Downloads

    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 331.35 KB

Citation

Please use this url to cite or link to this publication:

Chicago
VERBAEYS, CAROLINE, Piet Hoebeke, Simon Van Belle, and Sylvie Rottey. 2010. “Targeted Therapy for Metastatic Renal Cell Cancer.” Acta Clinica Belgica 65 (2): 115–121.
APA
VERBAEYS, CAROLINE, Hoebeke, P., Van Belle, S., & Rottey, S. (2010). Targeted therapy for metastatic renal cell cancer. ACTA CLINICA BELGICA, 65(2), 115–121.
Vancouver
1.
VERBAEYS C, Hoebeke P, Van Belle S, Rottey S. Targeted therapy for metastatic renal cell cancer. ACTA CLINICA BELGICA. 2010;65(2):115–21.
MLA
VERBAEYS, CAROLINE, Piet Hoebeke, Simon Van Belle, et al. “Targeted Therapy for Metastatic Renal Cell Cancer.” ACTA CLINICA BELGICA 65.2 (2010): 115–121. Print.
@article{1195855,
  abstract     = {Renal cell cancer is a common urological malignancy for which the incidence has doubled over the last three decades. 
Thirty percent of patients have metastatic disease at the moment of diagnosis. Thirty percent of the remaining surgically treated patients will develop metastases. 
Before the introduction of targeted therapies the only therapeutic option for these patients was immunotherapy with bad tolerability and poor results. 
This review discusses these new 'targeted therapies'.},
  author       = {VERBAEYS, CAROLINE and Hoebeke, Piet and Van Belle, Simon and Rottey, Sylvie},
  issn         = {0001-5512},
  journal      = {ACTA CLINICA BELGICA},
  keyword      = {IMMUNOTHERAPY,SUNITINIB,TEMSIROLIMUS,SORAFENIB,CARCINOMA,DOUBLE-BLIND,INTERFERON-ALPHA,PHASE-III TRIAL,targeted therapy,renal cell cancer,metastasis},
  language     = {eng},
  number       = {2},
  pages        = {115--121},
  title        = {Targeted therapy for metastatic renal cell cancer},
  volume       = {65},
  year         = {2010},
}

Web of Science
Times cited: